Effect of cashew nut and its oil on weight loss, blood pressure, sugar and fat in the blood, and bowel improvement in individuals at excess of weight
- Conditions
- Overweightobesitycardiometabolic risk factorsSH1.020.020.040.050
- Registration Number
- RBR-8xzkyp2
- Lead Sponsor
- niversidade Federal de Viçosa
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruitment completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Men and women between 20 and 55 years old; Excess weight (= 27 kg/m²), high waist circumference (= 80 cm for women; = 90 cm for men) and excess body fat (> 30% for women and > 20% for men) associated with another component of the Metabolic Syndrome: triglycerides =150 mg/dL; blood pressure = 130/85 mmHg) or fasting glucose =100 mg/dL or; Obesity (BMI = 30 kg/m²) regardless of the presence of other components of the Metabolic Syndrome.
Pregnant, lactating or menopausal women; Athletes; Smokers; Vegans; Shift workers; With a history of HIV, digestive, hepatic, renal, cardiovascular, thyroid, cancer, inflammatory diseases or eating disorders; Who have a history of drug and/or alcohol abuse; Aversion or allergy to nuts; Who has had an infection in the last month; Consume more than 30 g/day of nuts; Make use of certain medications such as anti-inflammatory drugs, corticoids and antibiotics; Have problems that can interfere with chewing; Weight instability (5% of usual weight) in the last 3 months; Alcohol consumption > 21 units (˜168g) per week; Consumption of vitamin, mineral and omega 3 supplements.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expected outcome 1- It is expected to find weight loss, which will be evaluated using the DEXA technique (Dual-energy X-ray Absortiometry) with fan-beam technology (Lunar Prodigy Advance 16 DXA System, version 13.31, GE Lunar ) at the beginning and end of the intervention, following the protocol recommended by the manufacturer, a weight loss of at least 4 kg is expected.
- Secondary Outcome Measures
Name Time Method Secondary outcome 1 - It is expected to find a reduction in blood pressure in patients who have alterations initialy, a reduction in inflammatory biomarkers and oxidative stress, as well as verifying aspects related to the gene expression of these markers.;Secondary outcome 2 - It is expected to find a positive modulation of the intestinal microbiota with improvement in dysbiosis and a reduction in intestinal permeability.;Secondary outcome 3 - It is expected to find relationships between cashew nut intake and its oil and neuroendocrine markers of satiety.;Secondary outcome 4 - It is expected to find possible influences of genetic polymorphisms and responses to treatments with the cashew nut and its oil.